M
Monika Morak
Researcher at Ludwig Maximilian University of Munich
Publications - 54
Citations - 3005
Monika Morak is an academic researcher from Ludwig Maximilian University of Munich. The author has contributed to research in topics: Lynch syndrome & Cancer. The author has an hindex of 23, co-authored 51 publications receiving 2240 citations. Previous affiliations of Monika Morak include Klinikum der Universität München.
Papers
More filters
Journal ArticleDOI
Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database
Pål Møller,Toni T. Seppälä,Inge Bernstein,Inge Bernstein,Elke Holinski-Feder,Paola Sala,D. Gareth Evans,Annika Lindblom,Finlay A. Macrae,Finlay A. Macrae,Ignacio Blanco,Rolf H. Sijmons,Jacqueline Jeffries,Hans F. A. Vasen,John Burn,Sigve Nakken,Eivind Hovig,Einar Andreas Rødland,Kukatharmini Tharmaratnam,Wouter H. de Vos tot Nederveen Cappel,James A. Hill,Juul T. Wijnen,Kate Green,Fiona Lalloo,Lone Sunde,Lone Sunde,Miriam Mints,Lucio Bertario,Marta Pineda,Matilde Navarro,Monika Morak,Laura Renkonen-Sinisalo,Ian M. Frayling,John-Paul Plazzer,Kirsi Pylvänäinen,Julian R. Sampson,Gabriel Capellá,Jukka-Pekka Mecklin,Gabriela Möslein +38 more
TL;DR: The four Lynch syndrome-associated genes had different penetrance and expression, and colorectal cancer occurred frequently despite colonoscopic surveillance but resulted in few deaths.
Journal ArticleDOI
Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database
Pål Møller,Toni T. Seppälä,Inge Bernstein,Inge Bernstein,Elke Holinski-Feder,Paulo Sala,D. Gareth Evans,D. Gareth Evans,Annika Lindblom,Finlay A. Macrae,Finlay A. Macrae,Ignacio Blanco,Rolf H. Sijmons,Jacqueline Jeffries,Hans F. A. Vasen,John Burn,Sigve Nakken,Eivind Hovig,Einar Andreas Rødland,Kukatharmini Tharmaratnam,Wouter H. de Vos tot Nederveen Cappel,James Hill,Juul T. Wijnen,Mark A. Jenkins,Kate Green,Kate Green,Fiona Lalloo,Fiona Lalloo,Lone Sunde,Miriam Mints,Lucio Bertario,Marta Pineda,Matilde Navarro,Monika Morak,Laura Renkonen-Sinisalo,Laura Renkonen-Sinisalo,Mev Dominguez Valentin,Ian M. Frayling,John-Paul Plazzer,Kirsi Pylvänäinen,Maurizio Genuardi,Jukka-Pekka Mecklin,Gabriela Moeslein,Julian R. Sampson,Gabriel Capellá +44 more
TL;DR: Carriers of different path_MMR variants exhibit distinct patterns of cancer risk and survival as they age, and risk estimates for counselling and planning of surveillance and treatment should be tailored to each patient’s age, gender and path-MMR variant.
Journal ArticleDOI
Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database
Mev Dominguez-Valentin,Julian R. Sampson,Toni T. Seppälä,Sanne W. ten Broeke,John-Paul Plazzer,Sigve Nakken,Christoph Engel,Stefan Aretz,Mark A. Jenkins,Lone Sunde,Lone Sunde,Inge Bernstein,Gabriel Capellá,Francesc Balaguer,Huw D. Thomas,D. Gareth Evans,D. Gareth Evans,John Burn,Marc S. Greenblatt,Eivind Hovig,Wouter H. de Vos tot Nederveen Cappel,Rolf H. Sijmons,Lucio Bertario,Maria Grazia Tibiletti,Giulia Martina Cavestro,Annika Lindblom,Adriana Della Valle,Francisco López-Köstner,Nathan Gluck,Lior H. Katz,Karl Heinimann,Carlos A. Vaccaro,Reinhard Büttner,Heike Görgens,Elke Holinski-Feder,Monika Morak,Stefanie Holzapfel,Robert Hüneburg,Magnus von Knebel Doeberitz,Magnus von Knebel Doeberitz,Markus Loeffler,Nils Rahner,Hans K. Schackert,Verena Steinke-Lange,Wolff Schmiegel,Deepak Vangala,Kirsi Pylvänäinen,Laura Renkonen-Sinisalo,Laura Renkonen-Sinisalo,John L. Hopper,Aung Ko Win,Robert W. Haile,Noralane M. Lindor,Steven Gallinger,Loic Le Marchand,Polly A. Newcomb,Jane C. Figueiredo,Stephen N. Thibodeau,Karin Wadt,Christina Therkildsen,Henrik Okkels,Zohreh Ketabi,Leticia Moreira,Ariadna Sánchez,Miquel Serra-Burriel,Marta Pineda,Matilde Navarro,Ignacio Blanco,Kate Green,Fiona Lalloo,Emma J Crosbie,James Hill,Oliver G. Denton,Ian M. Frayling,Einar Andreas Rødland,Hans F. A. Vasen,Miriam Mints,Florencia Neffa,Patricia Esperon,Karin Alvarez,Revital Kariv,Guy Rosner,Tamara Alejandra Piñero,María Laura Gonzalez,Pablo Kalfayan,Douglas Tjandra,Ingrid Winship,Ingrid Winship,Finlay A. Macrae,Finlay A. Macrae,Gabriela Möslein,Jukka-Pekka Mecklin,Maartje Nielsen,Pål Møller,Pål Møller +94 more
TL;DR: Management guidelines for Lynch syndrome may require revision in light of these different gene and gender-specific risks and the good prognosis for the most commonly associated cancers.
Journal ArticleDOI
Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study
Marlies Kempers,Roland P. Kuiper,Charlotte W. Ockeloen,Pierre O. Chappuis,Pierre Hutter,Nils Rahner,Hans K. Schackert,Verena Steinke,Elke Holinski-Feder,Monika Morak,Matthias Kloor,Reinhard Büttner,Eugène T P Verwiel,J. Han van Krieken,Iris D. Nagtegaal,Monique Goossens,Rachel S. van der Post,Renee C. Niessen,Rolf H. Sijmons,Irma Kluijt,Frans B. L. Hogervorst,Edward M Leter,Johan J.P. Gille,Cora M. Aalfs,Egbert J.W. Redeker,Frederik J. Hes,Carli M. J. Tops,Bernadette P M van Nesselrooij,Marielle E. van Gijn,Encarna B. Gomez Garcia,Diana Eccles,David J. Bunyan,Sapna Syngal,Elena M. Stoffel,Julie O. Culver,Melanie R. Palomares,Tracy Graham,Lea Velsher,János Papp,Edith Olah,Tsun Leung Chan,Suet Yi Leung,Ad Geurts van Kessel,Lambertus A. Kiemeney,Nicoline Hoogerbrugge,Marjolijn J L Ligtenberg +45 more
TL;DR: The results underscore the effect of mosaic MSH2 deficiency, leading to variable cancer risks, and could form the basis of an optimised protocol for the recognition and targeted prevention of cancer in EPCAM deletion carriers.
Journal ArticleDOI
Recurrence and Variability of Germline EPCAM Deletions in Lynch Syndrome
Roland P. Kuiper,Lisenka E.L.M. Vissers,Ramprasath Venkatachalam,Danielle Bodmer,Eveline Hoenselaar,Monique Goossens,Aline Haufe,Eveline J. Kamping,Renee C. Niessen,Frans B. L. Hogervorst,Johan J.P. Gille,B. Redeker,Carli M. J. Tops,Marielle E. van Gijn,Ans M.W. van den Ouweland,Nils Rahner,Verena Steinke,Philip Kahl,Elke Holinski-Feder,Monika Morak,Matthias Kloor,Susanne Stemmler,Beate Betz,Pierre Hutter,David J. Bunyan,Sapna Syngal,Julie O. Culver,Tracy Graham,Tsun Leung Chan,Iris D. Nagtegaal,J. Han van Krieken,Hans K. Schackert,Nicoline Hoogerbrugge,Ad Geurts van Kessel,Marjolijn J L Ligtenberg +34 more
TL;DR: 3′ end EPCAM deletions are a recurrent cause of Lynch syndrome, which should be implemented in routine Lynch syndrome diagnostics, and nonallelic homologous recombination as the most likely mechanism is concluded.